Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19.
Brain
COVID-19
Children
Neurofilament
Neurology
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
16
01
2021
accepted:
09
04
2021
revised:
08
04
2021
pubmed:
25
4
2021
medline:
14
10
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Serum neurofilament light chain (sNfL) is an established biomarker of neuro-axonal damage in multiple neurological disorders. Raised sNfL levels have been reported in adults infected with pandemic coronavirus disease 2019 (COVID-19). Levels in children infected with COVID-19 have not as yet been reported. To evaluate whether sNfL is elevated in children contracting COVID-19. Between May 22 and July 22, 2020, a network of outpatient pediatricians in Bavaria, Germany, the Coronavirus antibody screening in children from Bavaria study network (CoKiBa), recruited healthy children into a cross-sectional study from two sources: an ongoing prevention program for 1-14 years, and referrals of 1-17 years consulting a pediatrician for possible infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We determined sNfL levels by single molecule array immunoassay and SARS-CoV-2 antibody status by two independent quantitative methods. Of the 2652 included children, 148 (5.6%) were SARS-CoV-2 antibody positive with asymptomatic to moderate COVID-19 infection. Neurological symptoms-headache, dizziness, muscle aches, or loss of smell and taste-were present in 47/148 cases (31.8%). Mean sNfL levels were 5.5 pg/ml (SD 2.9) in the total cohort, 5.1 (SD 2.1) pg/ml in the children with SARS-CoV-2 antibodies, and 5.5 (SD 3.0) pg/ml in those without. Multivariate regression analysis revealed age-but neither antibody status, antibody levels, nor clinical severity-as an independent predictor of sNfL. Follow-up of children with pediatric multisystem inflammatory syndrome (n = 14) showed no association with sNfL. In this population study, children with asymptomatic to moderate COVID-19 showed no neurochemical evidence of neuronal damage.
Sections du résumé
BACKGROUND
BACKGROUND
Serum neurofilament light chain (sNfL) is an established biomarker of neuro-axonal damage in multiple neurological disorders. Raised sNfL levels have been reported in adults infected with pandemic coronavirus disease 2019 (COVID-19). Levels in children infected with COVID-19 have not as yet been reported.
OBJECTIVE
OBJECTIVE
To evaluate whether sNfL is elevated in children contracting COVID-19.
METHODS
METHODS
Between May 22 and July 22, 2020, a network of outpatient pediatricians in Bavaria, Germany, the Coronavirus antibody screening in children from Bavaria study network (CoKiBa), recruited healthy children into a cross-sectional study from two sources: an ongoing prevention program for 1-14 years, and referrals of 1-17 years consulting a pediatrician for possible infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We determined sNfL levels by single molecule array immunoassay and SARS-CoV-2 antibody status by two independent quantitative methods.
RESULTS
RESULTS
Of the 2652 included children, 148 (5.6%) were SARS-CoV-2 antibody positive with asymptomatic to moderate COVID-19 infection. Neurological symptoms-headache, dizziness, muscle aches, or loss of smell and taste-were present in 47/148 cases (31.8%). Mean sNfL levels were 5.5 pg/ml (SD 2.9) in the total cohort, 5.1 (SD 2.1) pg/ml in the children with SARS-CoV-2 antibodies, and 5.5 (SD 3.0) pg/ml in those without. Multivariate regression analysis revealed age-but neither antibody status, antibody levels, nor clinical severity-as an independent predictor of sNfL. Follow-up of children with pediatric multisystem inflammatory syndrome (n = 14) showed no association with sNfL.
CONCLUSIONS
CONCLUSIONS
In this population study, children with asymptomatic to moderate COVID-19 showed no neurochemical evidence of neuronal damage.
Identifiants
pubmed: 33893540
doi: 10.1007/s00415-021-10554-1
pii: 10.1007/s00415-021-10554-1
pmc: PMC8064423
doi:
Substances chimiques
Neurofilament Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3969-3974Subventions
Organisme : Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst
ID : TiKoCo19
Investigateurs
Bettina Aichholzer
(B)
Georg Mair
(G)
Michaela Wruk
(M)
Imke Reischl
(I)
Andreas Ambrosch
(A)
David Antos
(D)
Stephan von Koskull
(S)
Christian Becker
(C)
Elisabeth Beer
(E)
Hubert Schirmer
(H)
Georg Birkinger
(G)
Andreas Blueml
(A)
Heike Buntrock-Döpke
(H)
Mona Castrop
(M)
Jost Dieckerhoff
(J)
Renate Eichhorn
(R)
Dominik Ewald
(D)
Gudrun Fleck Alfred Heihoff
(GFA)
Jürgen Geuder
(J)
Jens Grombach
(J)
Peter Gutdeutsch
(P)
Florian Segerer
(F)
Thomas Habash
(T)
Sonja Habash
(S)
Susanne Harner
(S)
Christoph Herbst
(C)
Daniela Heuschmann
(D)
Meike Hofmann
(M)
Michael Horn
(M)
Birgit Jork-Kaeferlein
(B)
Monika Schwarz
(M)
Reinhard Hopfner
(R)
Guido Judex
(G)
Bastian Baumgartner
(B)
Monika Corbacioglu
(M)
Sabrina Lindner
(S)
Bettina Meinel
(B)
Alena Bauer
(A)
Hannes Löw
(H)
Annamaria Szulagyi-Kovacs
(A)
Sarah Laub
(S)
Annegret Klein
(A)
Cosima Koering
(C)
Niclas Landvogt
(N)
Claudia Soehngen
(C)
Karin Rasp
(K)
Gudrun Schick-Niedermeier
(G)
Marinus Laub
(M)
Otto Laub
(O)
Georg Leipold
(G)
Petra Schmid-Seibold
(P)
Johannes Pawlak
(J)
Michaela Reitz
(M)
Georg Puchner
(G)
David Peterhoff
(D)
Christiane Razeghi
(C)
Stefan Razeghi
(S)
Christine Rehe
(C)
Klaus Rehe
(K)
Matthias Scheffel
(M)
Ludwig Kaesbauer
(L)
Roland Schmid
(R)
Michael Strobelt
(M)
Nina Schoetzau
(N)
Andrea Schweiger-Kabesch
(A)
Marko Senjor
(M)
Michael Sperlich
(M)
Guenter Theuerer
(G)
Guenter Steidle
(G)
German Tretter
(G)
Victor von Arnim
(V)
Marlene Volz-Fleckenstein
(M)
Sebastian Einhauser
(S)
Patrick Neckermann
(P)
Natascha Borchers
(N)
Elisangela Santos-Valente
(E)
Parastoo Kheiroddin
(P)
Patricia Schöberl
(P)
Jakob Niggel
(J)
Stephan Gerling
(S)
Informations de copyright
© 2021. The Author(s).
Références
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
Infection. 2021 Feb;49(1):75-82
pubmed: 32827125
JAMA Neurol. 2020 Nov 1;77(11):1440-1445
pubmed: 32609336
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
J Neurol. 2020 Dec;267(12):3476-3478
pubmed: 32647900
JAMA Pediatr. 2021 Aug 1;175(8):837-845
pubmed: 33821923
J Child Neurol. 2021 Mar;36(4):324-330
pubmed: 33112694
J Neurol. 2021 Jul;268(7):2570-2577
pubmed: 33566157
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Mol Cell Pediatr. 2019 Jan 9;6(1):1
pubmed: 30627823
Nat Med. 2019 Feb;25(2):277-283
pubmed: 30664784
J Neurol Sci. 2020 Nov 15;418:117096
pubmed: 32823135
Neurology. 2020 Sep 22;95(12):e1754-e1759
pubmed: 32546655